Use of a VEGF antagonist to treat angiogenic eye disorders
The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
1. A method for treating age related macular degeneration in a patient in need thereof, comprising intravitreally administering, to said patient, an effective amount of aflibercept which is 2 mg approximately every 4 weeks for the first 3 months, followed by 2 mg approximately once every 8 weeks or once every 2 months.
2. The method of claim 1 , wherein the age-related macular degeneration is neovascular (wet).
3. The method of claim 2 wherein the patient loses less than 15 letters of Best Corrected Visual Acuity (BCVA) score.
4. The method of claim 3 wherein Best Corrected Visual Acuity (BCVA) is according to Early Treatment Diabetic Retinopathy Study (ETDRS) letter score.
5. The method of claim 2 wherein the patient gains at least 15 letters of Best Corrected Visual Acuity (BCVA) score.
6. The method of claim 5 wherein Best Corrected Visual Acuity (BCVA) is according to Early Treatment Diabetic Retinopathy Study (ETDRS) letter score.
7. The method of claim 1 , wherein approximately every 4 weeks comprises approximately every 28 days or approximately monthly.
8. The method of claim 7 , wherein the age-related macular degeneration is neovascular (wet).
9. The method of claim 8 wherein exclusion criteria for the patient include (1) active intraocular inflammation; or (2) active ocular or periocular infection.
10. A method for treating diabetic macular edema in a patient in need thereof, comprising intravitreally administering, to said patient, an effective amount of aflibercept which is 2 mg approximately every 4 weeks for the first 5 injections followed by 2 mg approximately once every 8 weeks or once every 2 months.
11. The method of claim 10 , wherein approximately every 4 weeks comprises approximately every 28 days or approximately monthly.
12. The method of claim 10 , further comprising, after 20 weeks, administering, via intravitreal injection, 2 mg of aflibercept once every 4 weeks.
13. The method of claim 10 wherein the patient loses less than 15 letters of Best Corrected Visual Acuity (BCVA) score.
14. The method of claim 13 wherein Best Corrected Visual Acuity (BCVA) is according to Early Treatment Diabetic Retinopathy Study (ETDRS) letter score.
15. The method of claim 10 wherein the patient gains at least 15 letters of Best Corrected Visual Acuity (BCVA) score.
16. The method of claim 15 wherein Best Corrected Visual Acuity (BCVA) is according to Early Treatment Diabetic Retinopathy Study (ETDRS) letter score.
17. The method of claim 10 wherein exclusion criteria for the patient include (1) active intraocular inflammation; or (2) active ocular or periocular infection.
18. A method for treating diabetic retinopathy in a patient in need thereof, comprising intravitreally administering, to said patient, an effective amount of aflibercept which is 2 mg approximately every 4 weeks for the first 5 injections followed by 2 mg approximately once every 8 weeks or 2 months.
19. The method of claim 18 , wherein approximately every 4 weeks comprises approximately every 28 days or approximately monthly.
20. The method of claim 19 wherein Best Corrected Visual Acuity (BCVA) is according to Early Treatment Diabetic Retinopathy Study (ETDRS) letter score.
21. The method of claim 18 , further comprising, after 20 weeks, administering, via intravitreal injection, 2 mg of aflibercept once every 4 weeks.
22. The method of claim 18 wherein the patient loses less than 15 letters of Best Corrected Visual Acuity (BCVA) score.
23. The method of claim 18 wherein the patient gains at least 15 letters of Best Corrected Visual Acuity (BCVA) score.
24. The method of claim 23 wherein Best Corrected Visual Acuity (BCVA) is according to Early Treatment Diabetic Retinopathy Study (ETDRS) letter score.
25. The method of claim 18 wherein exclusion criteria for the patient include (1) active intraocular inflammation; or (2) active ocular or periocular infection.
26. A method for treating diabetic retinopathy in a patient with diabetic macular edema, who is in need of such treatment, comprising intravitreally administering, to said patient, an effective amount of aflibercept which is 2 mg approximately every 4 weeks for the first 5 injections followed by 2 mg approximately once every 8 weeks or 2 months.
27. The method of claim 26 , wherein approximately every 4 weeks comprises approximately every 28 days or approximately monthly.
28. The method of claim 26 , further comprising, after 20 weeks, administering, via intravitreal injection, 2 mg of aflibercept once every 4 weeks.
29. The method of claim 26 wherein the patient loses less than 15 letters of Best Corrected Visual Acuity (BCVA) score.
30. The method of claim 29 wherein Best Corrected Visual Acuity (BCVA) is according to Early Treatment Diabetic Retinopathy Study (ETDRS) letter score.
31. The method of claim 26 wherein the patient gains at least 15 letters of Best Corrected Visual Acuity (BCVA) score.
32. The method of claim 31 wherein Best Corrected Visual Acuity (BCVA) is according to Early Treatment Diabetic Retinopathy Study (ETDRS) letter score.
33. The method of claim 26 wherein exclusion criteria for the patient include (1) active intraocular inflammation; or (2) active ocular or periocular infection.
34. A method for treating an angiogenic eye disorder in a patient in need thereof, said method comprising administering to the patient an effective sequential dosing regimen of a single initial dose of a VEGF antagonist, followed by one or more secondary doses of the VEGF antagonist, followed by one or more tertiary doses of the VEGF antagonist;
wherein each secondary dose is administered 4 weeks after the immediately preceding dose; and
wherein each tertiary dose is administered 8 weeks after the immediately preceding dose;
wherein the VEGF antagonist is a receptor-based chimeric molecule comprising
an immunoglobin-like (Ig) domain 2 of a first VEGF receptor which is VEGFR1 and an Ig domain 3 of a second VEGF receptor which is VEGFR2, and a multimerizing component.
35. The method of claim 34 wherein the VEGF antagonist is aflibercept.
36. The method of claim 35 wherein exclusion criteria for the patient include (1) active intraocular inflammation; or (2) active ocular or periocular infection.
37. The method of claim 34 , wherein all doses of the VEGF antagonist are administered to the patient by intraocular administration.
38. The method of claim 37 , wherein the intraocular administration is intravitreal administration.
39. The method of claim 38 , wherein all doses of the VEGF antagonist comprise from about 0.5 mg to about 2 mg of the VEGF antagonist.
40. The method of claim 39 , wherein all doses of the VEGF antagonist comprise 0.5 mg of the VEGF antagonist.
41. The method of claim 39 , wherein all doses of the VEGF antagonist comprise 2 mg of the VEGF antagonist.
42. The method of claim 34 , wherein the angiogenic eye disorder is selected from the group consisting of: age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
43. The method of claim 34 wherein the angiogenic eye disorder is age related macular degeneration.
44. The method of claim 43 wherein all doses of VEGF antagonist comprise 0.5 mg of the VEGF antagonist.
45. The method of claim 43 wherein all doses of VEGF antagonist comprise 2.0 mg of the VEGF antagonist.
46. The method of claim 34 wherein the angiogenic eye disorder is diabetic retinopathy.
47. The method of claim 34 , wherein the angiogenic eye disorder is diabetic macular edema.